Physician profile
Joseph Giovanetti
NPI 1619003787
$2,546.41
in general payments reported to CMS, 2019-2025
18 companies · $166 in 2025
The $166 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $409 · 2020: $235 · 2021: $283 · 2022: $369 · 2023: $357 · 2024: $728 · 2025: $166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,227 · Entertainment: $23.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,227.04 |
| Entertainment | $23.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Visioneering Technologies, INC. | $576.02 | 2019-2024 | |
| Bausch & Lomb Americas INC. | $365.94 | 2022-2025 | Infuse, Xiidra, Miebo |
| Coopervision INC. | $326.24 | 2019-2025 | Clariti Contact Lens |
| Johnson & Johnson Vision Care, INC. | $294.93 | 2019-2024 | Acuvue |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $270.74 | 2019-2021 | |
| Alcon Vision LLC | $244.19 | 2019-2025 | Precision 1, Dailies, Precision7 |
| Sun Pharmaceutical Industries INC. | $86.98 | 2021-2023 | Cequa |
| Abbvie INC. | $74.86 | 2022-2025 | |
| Tarsus Pharmaceuticals, INC. | $50.85 | 2024-2025 | Xdemvy |
| Thea Pharma INC. | $48.88 | 2024-2025 | Iyuzeh |
| Shire North American Group INC | $44.43 | 2019 | |
| Oyster Point Pharma, INC. | $42.22 | 2022-2023 | Tyrvaya |
| Abb Con-Cise Optical Group LLC | $38.10 | 2020-2021 | |
| Optos, INC. | $23.63 | 2024 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Synergeyes, INC. | $18.46 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $16.11 | 2022 | |
| Kala Pharmaceuticals, INC. | $13.39 | 2021 | |
| Maculogix, INC. | $10.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Giovanetti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.